Impact of COVID-19 on cancer incidence, presentation, diagnosis, treatment and survival in Northern Ireland
© 2024 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC..
The COVID-19 pandemic had a major impact on cancer patients and services but has been difficult to quantify. We examined how the entire cancer pathway-from incidence, presentation, diagnosis, stage, treatment and survival-was affected in Northern Ireland during April-December 2020 compared to equivalent 2018-2019 periods using retrospective, observational cancer registry data from the Northern Ireland Cancer Registry (NICR). There were 6748 cancer cases in April-December 2020 and an average 7724 patients in April-December 2018-2019. Incident cases decreased by 13% (almost 1000). Significant differences were found across age cohorts and deprivation quintiles, with reductions greatest for younger people (<55 years; 19% decrease) and less deprived (22% decrease). A higher proportion had emergency admission (16%-to-20%) with lower proportions diagnosed pathologically (85%-to-83%). There was a significant stage shift, with lower proportions of early stage (29%-to-25%) and higher late-stage (21%-to-23%). Lower proportions received surgery (41%-to-38%) and radiotherapy (24%-to-22%) with a higher proportion not receiving treatment (29%-to-33%). One-year observed-survival decreased from 73.7% to 69.8% and 1-year net-survival decreased from 76.1% to 72.9%, with differences driven by five tumours; Lung (40.3%-to-35.0%), Head-and-Neck (77.4%-to-68.4%), Oesophageal (53.5%-to-42.3%), Lymphoma (81.1%-to-75.2%) and Uterine cancer (87.4%-to-80.4%). Our study reveals profound adverse impact of COVID-19 on the entire cancer patient pathway, with 13% fewer cases, greater emergency admissions and significant stage-shift from early to more advanced-stage disease. There was major treatment impact with lower rates of surgery and radiotherapy and higher proportions receiving no treatment. There were significant reductions in 1-year survival. Our study will support service recovery and protect cancer services in future pandemics or disruptions.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:154 |
---|---|
Enthalten in: |
International journal of cancer - 154(2024), 10 vom: 15. März, Seite 1731-1744 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Bennett, Damien [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 14.03.2024 Date Revised 14.03.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1002/ijc.34847 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM367585839 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM367585839 | ||
003 | DE-627 | ||
005 | 20240314234945.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240125s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/ijc.34847 |2 doi | |
028 | 5 | 2 | |a pubmed24n1329.xml |
035 | |a (DE-627)NLM367585839 | ||
035 | |a (NLM)38268160 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Bennett, Damien |e verfasserin |4 aut | |
245 | 1 | 0 | |a Impact of COVID-19 on cancer incidence, presentation, diagnosis, treatment and survival in Northern Ireland |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.03.2024 | ||
500 | |a Date Revised 14.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2024 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. | ||
520 | |a The COVID-19 pandemic had a major impact on cancer patients and services but has been difficult to quantify. We examined how the entire cancer pathway-from incidence, presentation, diagnosis, stage, treatment and survival-was affected in Northern Ireland during April-December 2020 compared to equivalent 2018-2019 periods using retrospective, observational cancer registry data from the Northern Ireland Cancer Registry (NICR). There were 6748 cancer cases in April-December 2020 and an average 7724 patients in April-December 2018-2019. Incident cases decreased by 13% (almost 1000). Significant differences were found across age cohorts and deprivation quintiles, with reductions greatest for younger people (<55 years; 19% decrease) and less deprived (22% decrease). A higher proportion had emergency admission (16%-to-20%) with lower proportions diagnosed pathologically (85%-to-83%). There was a significant stage shift, with lower proportions of early stage (29%-to-25%) and higher late-stage (21%-to-23%). Lower proportions received surgery (41%-to-38%) and radiotherapy (24%-to-22%) with a higher proportion not receiving treatment (29%-to-33%). One-year observed-survival decreased from 73.7% to 69.8% and 1-year net-survival decreased from 76.1% to 72.9%, with differences driven by five tumours; Lung (40.3%-to-35.0%), Head-and-Neck (77.4%-to-68.4%), Oesophageal (53.5%-to-42.3%), Lymphoma (81.1%-to-75.2%) and Uterine cancer (87.4%-to-80.4%). Our study reveals profound adverse impact of COVID-19 on the entire cancer patient pathway, with 13% fewer cases, greater emergency admissions and significant stage-shift from early to more advanced-stage disease. There was major treatment impact with lower rates of surgery and radiotherapy and higher proportions receiving no treatment. There were significant reductions in 1-year survival. Our study will support service recovery and protect cancer services in future pandemics or disruptions | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a COVID-19 impact | |
650 | 4 | |a cancer | |
650 | 4 | |a stage | |
650 | 4 | |a survival | |
650 | 4 | |a treatment | |
700 | 1 | |a Murray, Inez |e verfasserin |4 aut | |
700 | 1 | |a Mitchell, Helen |e verfasserin |4 aut | |
700 | 1 | |a Gavin, Anna |e verfasserin |4 aut | |
700 | 1 | |a Donnelly, David |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t International journal of cancer |d 1966 |g 154(2024), 10 vom: 15. März, Seite 1731-1744 |w (DE-627)NLM000004383 |x 1097-0215 |7 nnns |
773 | 1 | 8 | |g volume:154 |g year:2024 |g number:10 |g day:15 |g month:03 |g pages:1731-1744 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/ijc.34847 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 154 |j 2024 |e 10 |b 15 |c 03 |h 1731-1744 |